S100A10 and ovarian serous adenocarcinoma: Ongoing studies in our laboratory are investigating the ability of ATRA to inhibit cell proliferation and S100A10 expression in a range of serous ovarian cancer cell lines and serous ovarian cancer tissues using an ex-vivo explant assay [113].